MissionIR News – Seeking Alpha Blog Features Cardium Therapeutics

Company positions itself for rapid growth via multi-prong strategy

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities...

Atlanta, GA (PRWEB) July 05, 2012

MissionIR would like to highlight Cardium Therapeutics, Inc. (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations.

Today, Seeking Alpha published the following blog featuring CXM: http://seekingalpha.com/instablog/783255-missionir/818221-cardium-therapeutics-inc-cxm-gearing-up-for-growth

The blog, titled “Cardium Therapeutics, Inc. (CXM): Gearing Up For Growth,” provides a comprehensive overview of the company and its three primary business lines. Cardium’s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value.

Key investment highlights presented include:

  • Diversified Portfolio of Medical Products with Large Market Potentials
  • Phase 3 Registration Study Underway for DNA-based Generx Product Candidate
  • U.S. and International Commercialization Agreements for FDA-Cleared Excellagen Product
  • Roll out of MedPodium Nutra-Apps Products across the U.S.
  • Continued Evaluation of New Products and Technologies to Expand Portfolio

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Contact